Delayed Salary Quotes

In each case, the relative cost of postponing the purchase for buyer and seller determines the intensity of competition between the [past and future] selves of the seller. If the buyer has a lower cost of postponing the purchase (delay, making do with an interior model) than the seller (inventory, staff salaries) the buyer has the bargaining power.

Another delegate in the House had this to say: “Oklahomans are tired of being ruled by federal bureaucrats and judges, none of them elected. They decide everything from what can be taught in the public schools to what can be served to kids for lunch and whether the kids can have a prayer. They decree that welfare recipients are entitled to a color television and cell phone, all paid for by the working families of Oklahoma, some of whom can afford neither. They claim they have the right to regulate every creek, farm pond, mudhole, and wet spot in America, including here in Oklahoma. We have to pay for their crackpot regulations based on crackpot science, or no science at all. We have to pay the salaries of the bureaucrats and put up with the endless delays and mountainous paperwork. It’s high time to put a stop to bureaucrats and judges running our lives. Let’s take back control. Independence today, tomorrow, and forever.

Conservatives have proposed cutting pension plans and benefits like contributions to health care. Think for a moment what pensions are: Pensions are delayed payments for work already done. If employees’ pensions are cut, the company is stealing their money—money they have already earned. If the corporation says it can no longer pay “generous” benefits, then the company is cutting employees’ salaries. “Benefits” are not gifts; “generosity” is not at issue. Benefits are part of pay for work. Corporations

From the outset, hydroxychloroquine (HCQ) and other therapeutics posed an existential threat to Dr. Fauci and Bill Gates’ $48 billion COVID vaccine project, and particularly to their vanity drug remdesivir, in which Gates has a large stake.1 Under federal law, new vaccines and medicines cannot quality for Emergency Use Authorization (EUA) if any existing FDA-approved drug proves effective against the same malady: For FDA to issue an EUA (emergency use authorization), there must be no adequate, approved, and available alternative to the candidate product for diagnosing, preventing, or treating the disease or condition. . . .2 Thus, if any FDA-approved drug like hydroxychloroquine (or ivermectin) proved effective against COVID, pharmaceutical companies would no longer be legally allowed to fast-track their billion-dollar vaccines to market under Emergency Use Authorization. Instead, vaccines would have to endure the years-long delays that have always accompanied methodical safety and efficacy testing, and that would mean less profits, more uncertainty, longer runways to market, and a disappointing end to the lucrative COVID-19 vaccine gold rush. Dr. Fauci has invested $6 billion in taxpayer lucre in the Moderna vaccine alone.3 His agency is co-owner4 of the patent and stands to collect a fortune in royalties. At least four of Fauci’s hand-picked deputies are in line to collect royalties of $150,000/year based on Moderna’s success, and that’s on top of the salaries already paid by the American public.5,6

Under federal law, new vaccines and medicines cannot quality for Emergency Use Authorization (EUA) if any existing FDA-approved drug proves effective against the same malady: For FDA to issue an EUA (emergency use authorization), there must be no adequate, approved, and available alternative to the candidate product for diagnosing, preventing, or treating the disease or condition. . . .2 Thus, if any FDA-approved drug like hydroxychloroquine (or ivermectin) proved effective against COVID, pharmaceutical companies would no longer be legally allowed to fast-track their billion-dollar vaccines to market under Emergency Use Authorization. Instead, vaccines would have to endure the years-long delays that have always accompanied methodical safety and efficacy testing, and that would mean less profits, more uncertainty, longer runways to market, and a disappointing end to the lucrative COVID-19 vaccine gold rush. Dr. Fauci has invested $6 billion in taxpayer lucre in the Moderna vaccine alone.3 His agency is co-owner4 of the patent and stands to collect a fortune in royalties. At least four of Fauci’s hand-picked deputies are in line to collect royalties of $150,000/year based on Moderna’s success, and that’s on top of the salaries already paid by the American public.5

Instead, vaccines would have to endure the years-long delays that have always accompanied methodical safety and efficacy testing, and that would mean less profits, more uncertainty, longer runways to market, and a disappointing end to the lucrative COVID-19 vaccine gold rush. Dr. Fauci has invested $6 billion in taxpayer lucre in the Moderna vaccine alone.3 His agency is co-owner4 of the patent and stands to collect a fortune in royalties. At least four of Fauci’s hand-picked deputies are in line to collect royalties of $150,000/year based on Moderna’s success, and that’s on top of the salaries already paid by the American public.5,6

Among the deficiencies common to the Italian and the U.S. postal systems are: - inefficiency, and delays in deliveries - old-fashioned organization - low efficiency and low salaries of personnel - high frequency of strikes - very high operational deficit - Roberto Vacca, The Coming Dark Age

If any FDA-approved drug like hydroxychloroquine (or ivermectin) proved effective against COVID, pharmaceutical companies would no longer be legally allowed to fast-track their billion-dollar vaccines to market under Emergency Use Authorization. Instead, vaccines would have to endure the years-long delays that have always accompanied methodical safety and efficacy testing, and that would mean less profits, more uncertainty, longer runways to market, and a disappointing end to the lucrative COVID-19 vaccine gold rush. Dr. Fauci has invested $6 billion in taxpayer lucre in the Moderna vaccine alone. His agency is co-owner of the patent and stands to collect a fortune in royalties. At least four of Fauci’s hand-picked deputies are in line to collect royalties of $150,000/year based on Moderna’s success, and that’s on top of the salaries already paid by the American public.